Dmitry Balyasny’s Charles River Laboratories CRL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $248K | Sell |
1,093
-10,983
| -91% | -$1.96M | ﹤0.01% | 2760 |
|
|
2026
Q1 | $2.08M | Sell |
12,076
-196,483
| -94% | -$36.4M | ﹤0.01% | 1760 |
|
|
2025
Q4 | $41.6M | Buy |
208,559
+57,204
| +38% | +$10.4M | 0.05% | 403 |
|
|
2025
Q3 | $23.7M | Sell |
151,355
-282,871
| -65% | -$44.9M | 0.03% | 644 |
|
|
2025
Q2 | $65.9M | Buy |
434,226
+381,432
| +722% | +$50.9M | 0.1% | 240 |
|
|
2025
Q1 | $7.95M | Buy |
52,794
+47,094
| +826% | +$7.9M | 0.01% | 1043 |
|
|
2024
Q4 | $1.05M | Buy |
+5,700
| New | +$1.1M | ﹤0.01% | 1931 |
|
|
2024
Q3 | – | Sell |
-2,194
| Closed | -$453K | – | 2798 |
|
|
2024
Q2 | $453K | Sell |
2,194
-7,503
| -77% | -$1.7M | ﹤0.01% | 2088 |
|
|
2024
Q1 | $2.63M | Buy |
9,697
+318
| +3% | +$75.9K | ﹤0.01% | 1461 |
|
|
2023
Q4 | $2.22M | Sell |
9,379
-60,205
| -87% | -$11.8M | ﹤0.01% | 1419 |
|
|
2023
Q3 | $13.6M | Buy |
69,584
+42,594
| +158% | +$8.74M | 0.03% | 721 |
|
|
2023
Q2 | $5.67M | Buy |
26,990
+6,519
| +32% | +$1.3M | 0.01% | 1013 |
|
|
2023
Q1 | $4.13M | Sell |
20,471
-49,224
| -71% | -$11.2M | 0.01% | 1160 |
|
|
2022
Q4 | $15.2M | Buy |
+69,695
| New | +$15.2M | 0.04% | 584 |
|
|
2022
Q3 | – | Sell |
-1,348
| Closed | -$288K | – | 2907 |
|
|
2022
Q2 | $288K | Buy |
+1,348
| New | +$329K | ﹤0.01% | 2109 |
|
|
2022
Q1 | – | Sell |
-10,197
| Closed | -$3.84M | – | 2530 |
|
|
2021
Q4 | $3.84M | Buy |
+10,197
| New | +$3.96M | 0.01% | 942 |
|
|
2019
Q4 | – | Sell |
-23,539
| Closed | -$3.12M | – | 1202 |
|
|
2019
Q3 | $3.12M | Sell |
23,539
-62,311
| -73% | -$8.35M | 0.02% | 638 |
|
|
2019
Q2 | $12.2M | Buy |
85,850
+82,639
| +2,574% | +$11.2M | 0.08% | 355 |
|
|
2019
Q1 | $466K | Sell |
3,211
-3,744
| -54% | -$492K | ﹤0.01% | 1220 |
|
|
2018
Q4 | $787K | Buy |
+6,955
| New | +$871K | 0.01% | 971 |
|
|
2018
Q3 | – | Sell |
-2,162
| Closed | -$243K | – | 1717 |
|
|
2018
Q2 | $243K | Buy |
+2,162
| New | +$234K | ﹤0.01% | 1581 |
|
|
2018
Q1 | – | Sell |
-3,200
| Closed | -$350K | – | 1992 |
|
|
2017
Q4 | $350K | Buy |
3,200
+1,228
| +62% | +$134K | ﹤0.01% | 1677 |
|
|
2017
Q3 | $213K | Sell |
1,972
-13,945
| -88% | -$1.43M | ﹤0.01% | 1684 |
|
|
2017
Q2 | $1.61M | Sell |
15,917
-15,491
| -49% | -$1.43M | 0.01% | 983 |
|
|
2017
Q1 | $2.83M | Sell |
31,408
-224,696
| -88% | -$19.1M | 0.01% | 832 |
|
|
2016
Q4 | $19.5M | Buy |
256,104
+165,933
| +184% | +$12.6M | 0.1% | 279 |
|
|
2016
Q3 | $7.51M | Sell |
90,171
-67,619
| -43% | -$5.67M | 0.04% | 442 |
|
|
2016
Q2 | $13M | Buy |
157,790
+74,000
| +88% | +$6.1M | 0.08% | 298 |
|
|
2016
Q1 | $6.36M | Buy |
83,790
+78,921
| +1,621% | +$5.84M | 0.04% | 494 |
|
|
2015
Q4 | $391K | Sell |
4,869
-65,131
| -93% | -$4.7M | ﹤0.01% | 894 |
|
|
2015
Q3 | $4.45M | Buy |
70,000
+15,914
| +29% | +$1.14M | 0.03% | 546 |
|
|
2015
Q2 | $3.8M | Buy |
+54,086
| New | +$4M | 0.02% | 658 |
|
|
2014
Q2 | – | Sell |
-123,993
| Closed | -$7.48M | – | 654 |
|
|
2014
Q1 | $7.48M | Buy |
123,993
+37,357
| +43% | +$2.18M | 0.09% | 292 |
|
|
2013
Q4 | $4.59M | Buy |
+86,636
| New | +$4.35M | 0.06% | 318 |
|
Other funds holding CRL
AI
Dmitry Balyasny's CRL Position: Q2 2026 in Review
Dmitry Balyasny reduced its Charles River Laboratories (CRL) stake by 91% in Q2 2026, selling an estimated $1.96M and leaving 1,093 shares worth $248K. The position accounts for ﹤0.01% of the portfolio, ranked #2760.
Dmitry Balyasny first reported a position in CRL in Q4 2013 and has held it in 34 quarters since. The position peaked at $65.9M in Q2 2025. 563 funds tracked by Wall St. Rank hold CRL as of Q2 2026.
- Dmitry Balyasny held 1,093 shares of Charles River Laboratories worth $248K as of Q2 2026.
- Dmitry Balyasny sold 10,983 Charles River Laboratories shares in Q2 2026, an estimated $1.96M.
- Charles River Laboratories made up ﹤0.01% of Dmitry Balyasny's portfolio in Q2 2026, its #2760 holding.
- Dmitry Balyasny first reported a position in Charles River Laboratories in Q4 2013 and has held it in 34 quarters since.
- Dmitry Balyasny's Charles River Laboratories position peaked at $65.9M in Q2 2025.
- 563 funds tracked by Wall St. Rank held Charles River Laboratories as of Q2 2026.
Based on Balyasny Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.